These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 11901238)

  • 21. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis.
    Debette S; Markus HS
    BMJ; 2010 Jul; 341():c3666. PubMed ID: 20660506
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Incident lacunes preferentially localize to the edge of white matter hyperintensities: insights into the pathophysiology of cerebral small vessel disease.
    Duering M; Csanadi E; Gesierich B; Jouvent E; Hervé D; Seiler S; Belaroussi B; Ropele S; Schmidt R; Chabriat H; Dichgans M
    Brain; 2013 Sep; 136(Pt 9):2717-26. PubMed ID: 23864274
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Progression of cerebral white matter lesions in Alzheimer's disease: a new window for therapy?
    de Leeuw FE; Barkhof F; Scheltens P
    J Neurol Neurosurg Psychiatry; 2005 Sep; 76(9):1286-8. PubMed ID: 16107369
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Patchy changes in white matter in cranial computerized and magnetic resonance tomography--significance for (differential) diagnosis of dementia of the Alzheimer type and vascular dementia].
    Stoppe G; Staedt J; Bruhn H
    Fortschr Neurol Psychiatr; 1995 Nov; 63(11):425-40. PubMed ID: 8575717
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Markers of endothelial and hemostatic activation and progression of cerebral white matter hyperintensities: longitudinal results of the Austrian Stroke Prevention Study.
    Markus HS; Hunt B; Palmer K; Enzinger C; Schmidt H; Schmidt R
    Stroke; 2005 Jul; 36(7):1410-4. PubMed ID: 15905468
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Progression of white matter hyperintensities and incidence of new lacunes over a 3-year period: the Leukoaraiosis and Disability study.
    Gouw AA; van der Flier WM; Fazekas F; van Straaten EC; Pantoni L; Poggesi A; Inzitari D; Erkinjuntti T; Wahlund LO; Waldemar G; Schmidt R; Scheltens P; Barkhof F;
    Stroke; 2008 May; 39(5):1414-20. PubMed ID: 18323505
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Are MRI white matter lesions clinically significant in the 'old-old'? Evidence from the Sydney Older Persons Study.
    Piguet O; Ridley L; Grayson DA; Bennett HP; Creasey H; Lye TC; Broe GA
    Dement Geriatr Cogn Disord; 2003; 15(3):143-50. PubMed ID: 12584429
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Progression of cerebral small vessel disease in relation to risk factors and cognitive consequences: Rotterdam Scan study.
    van Dijk EJ; Prins ND; Vrooman HA; Hofman A; Koudstaal PJ; Breteler MM
    Stroke; 2008 Oct; 39(10):2712-9. PubMed ID: 18635849
    [TBL] [Abstract][Full Text] [Related]  

  • 29. White matter lesion progression: a surrogate endpoint for trials in cerebral small-vessel disease.
    Schmidt R; Scheltens P; Erkinjuntti T; Pantoni L; Markus HS; Wallin A; Barkhof F; Fazekas F
    Neurology; 2004 Jul; 63(1):139-44. PubMed ID: 15249623
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correlating Cognitive Decline with White Matter Lesion and Brain Atrophy Magnetic Resonance Imaging Measurements in Alzheimer's Disease.
    Bilello M; Doshi J; Nabavizadeh SA; Toledo JB; Erus G; Xie SX; Trojanowski JQ; Han X; Davatzikos C
    J Alzheimers Dis; 2015; 48(4):987-94. PubMed ID: 26402108
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictors for cognitive decline in patients with confluent white matter hyperintensities.
    Mok V; Xiong Y; Wong KK; Wong A; Schmidt R; Chu WW; Hu X; Lung Leung EY; Chen S; Chen Y; Tang WK; Chen X; Ho CL; Wong KS; Wong ST
    Alzheimers Dement; 2012 Oct; 8(5 Suppl):S96-S103. PubMed ID: 22651941
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Different impacts of blood pressure variability on the progression of cerebral microbleeds and white matter lesions.
    Liu W; Liu R; Sun W; Peng Q; Zhang W; Xu E; Cheng Y; Ding M; Li Y; Hong Z; Wu J; Zeng J; Yao C; Huang Y;
    Stroke; 2012 Nov; 43(11):2916-22. PubMed ID: 22949472
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Brain atrophy and white matter hyperintensity change in older adults and relationship to blood pressure. Brain atrophy, WMH change and blood pressure.
    Firbank MJ; Wiseman RM; Burton EJ; Saxby BK; O'Brien JT; Ford GA
    J Neurol; 2007 Jun; 254(6):713-21. PubMed ID: 17446997
    [TBL] [Abstract][Full Text] [Related]  

  • 34. White matter and subcortical gray matter lesion volume changes and late-life depression outcome: a 4-year magnetic resonance imaging study.
    Chen PS; McQuoid DR; Payne ME; Steffens DC
    Int Psychogeriatr; 2006 Sep; 18(3):445-56. PubMed ID: 16478567
    [TBL] [Abstract][Full Text] [Related]  

  • 35. White matter lesions - age-adjusted values for cognitively healthy and demented subjects.
    Hentschel F; Damian M; Krumm B; Froelich L
    Acta Neurol Scand; 2007 Mar; 115(3):174-80. PubMed ID: 17295712
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Periventricular white matter hyperintensities and the risk of dementia: a CREDOS study.
    Kim S; Choi SH; Lee YM; Kim MJ; Kim YD; Kim JY; Park JH; Myung W; Na HR; Han HJ; Shim YS; Kim JH; Yoon SJ; Kim SY; Kim DK
    Int Psychogeriatr; 2015 Dec; 27(12):2069-77. PubMed ID: 26212042
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiovascular risk and white matter lesions after endocrine control of Cushing's syndrome.
    Santos A; Resmini E; Gómez-Ansón B; Crespo I; Granell E; Valassi E; Pires P; Vives-Gilabert Y; Martínez-Momblán MA; de Juan M; Mataró M; Webb SM
    Eur J Endocrinol; 2015 Dec; 173(6):765-75. PubMed ID: 26497546
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low cerebrospinal fluid sulfatide predicts progression of white matter lesions: The LADIS study.
    Jonsson M; Zetterberg H; Rolstad S; Edman A; Gouw AA; Bjerke M; Lind K; Blennow K; Pantoni L; Inzitari D; Wallin A
    Dement Geriatr Cogn Disord; 2012; 34(1):61-7. PubMed ID: 22922641
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enzyme replacement therapy stabilized white matter lesion progression in Fabry disease.
    Fellgiebel A; Gartenschläger M; Wildberger K; Scheurich A; Desnick RJ; Sims K
    Cerebrovasc Dis; 2014; 38(6):448-56. PubMed ID: 25502511
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [White matter alterations in neurodegenerative and vascular dementia].
    Supprian T; Kessler H; Retz W; Rösler M; Grunwald I; Reith W; Falkai P
    Radiologe; 2003 Jul; 43(7):543-51. PubMed ID: 12955217
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.